<DOC>
	<DOCNO>NCT00782561</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability FG-3019 administer 8 week adolescent adult subject steroid-resistant focal segmental glomerulosclerosis ( FSGS ) .</brief_summary>
	<brief_title>Safety Pharmacokinetics FG-3019 Adolescents Adults With Focal Segmental Glomerulosclerosis ( FSGS )</brief_title>
	<detailed_description />
	<mesh_term>Glomerulosclerosis , Focal Segmental</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Age 1264 year , inclusive , girl age 1011 year , inclusive Tanner stage 3 great 2 . Biopsy diagnosis primary FSGS biopsy confirm centrally 3 . Age less equal 2 year old onset proteinuria 4 . First morning urine protein/creatinine ratio ( U p/c ) &gt; 1 gm/gm 5 . Estimated glomerular filtration rate great equal 40 mL/min/1.73 m2 1 . NonFSGS renal disease benign cyst ; secondary FSGS 2 . History organ transplantation 3 . History allergic anaphylactic reaction human , humanize , chimeric murine monoclonal antibody 4 . History malignancy , cardiovascular disease , diabetes mellitus , sickle cell disease , multiple sclerosis , systemic lupus erythematosus , active recurrent serious infection ( include limit Hepatitis B , Hepatitis C , HIV ) 5 . Participation study investigational drug within 6 week prior Day 0 receipt investigational drug within 12 week prior Day 0 6 . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2.5 time upper limit normal 7 . Hematocrit &lt; 30 %</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>steroid resistant focal segmental glomerulosclerosis</keyword>
	<keyword>FSGS</keyword>
	<keyword>adolescent focal segmental glomerulosclerosis</keyword>
	<keyword>focal segmental glomerulosclerosis</keyword>
</DOC>